Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
TPE:1720'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.45 Med: 1.29 Max: 1.68
Current: 0.49
During the past 13 years, the highest Debt-to-EBITDA Ratio of Standard Chemical & Pharmaceutical Co was 1.68. The lowest was 0.45. And the median was 1.29.
TPE:1720's Debt-to-EBITDA is ranked better than 71.99% of 682
companies
in the Drug Manufacturers industry
Industry Median: 1.59
vs TPE:1720: 0.49
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Standard Chemical & Pharmaceutical Co Debt-to-EBITDA Related Terms
Standard Chemical & Pharmaceutical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard Chemical & Pharmaceutical Co Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Standard Chemical & Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard Chemical & Pharmaceutical Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Standard Chemical & Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Standard Chemical & Pharmaceutical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Standard Chemical & Pharmaceutical Co (TPE:1720) has a Debt-to-EBITDA of 0.47 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Standard Chemical & Pharmaceutical Co. This is 64% below median its historical median of 1.29. Over the past decade, Standard Chemical & Pharmaceutical Co's Debt-to-EBITDA has ranged from 0.45 to 1.68. According to the industry distribution chart, Standard Chemical & Pharmaceutical Co ranks #191 out of 682 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is Standard Chemical & Pharmaceutical Co's Debt-to-EBITDA too high?
Standard Chemical & Pharmaceutical Co's current Debt-to-EBITDA of 0.47 is 64% below median its 10-year median of 1.29. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 1.68. The Drug Manufacturers industry median Debt-to-EBITDA is 1.59. Standard Chemical & Pharmaceutical Co's value of 0.47 is 70.4% below this industry median. Based on the distribution chart, Standard Chemical & Pharmaceutical Co ranks #191 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Standard Chemical & Pharmaceutical Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard Chemical & Pharmaceutical Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Standard Chemical & Pharmaceutical Co ranks #191 out of 682 companies for Debt-to-EBITDA. This puts Standard Chemical & Pharmaceutical Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.59. Standard Chemical & Pharmaceutical Co's value of 0.47 is 70.4% below this benchmark. Historically, Standard Chemical & Pharmaceutical Co's own Debt-to-EBITDA has ranged from 0.45 to 1.68 over the past decade. While the company's 10-year median is 1.29 vs. the industry median of 1.59, Standard Chemical & Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.59, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard Chemical & Pharmaceutical Co's current Debt-to-EBITDA of 0.47 is 70.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Standard Chemical & Pharmaceutical Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard Chemical & Pharmaceutical Co's current Debt-to-EBITDA is 0.47, which is 64% below median its own 10-year median of 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard Chemical & Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Standard Chemical & Pharmaceutical Co (TPE:1720) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.91, compared to a current price of NT$57.20 — trading 2.9% below its estimated fair value. The current Debt-to-EBITDA is 0.47, which is 64% below median its 10-year median of 1.29 and 70.4% below the Drug Manufacturers industry median of 1.59. Standard Chemical & Pharmaceutical Co's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Standard Chemical & Pharmaceutical Co (TPE:1720), the current Debt-to-EBITDA is 0.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard Chemical & Pharmaceutical Co (TPE:1720) Overvalued in 2026?
Based on GuruFocus' analysis, Standard Chemical & Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$57.20 is trading 2.9% below its estimated GF Value™ of NT$58.91.
GuruFocus considers Standard Chemical & Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1720:
Debt-to-EBITDA: 0.47 (64% below median its 10-year median of 1.29)
GF Value™: NT$58.91 vs. price of NT$57.20 (2.9% below fair value)
Industry Position: 70.4% below the Drug Manufacturers median (#191 of 682)
No single metric tells the full story. See the TPE:1720 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard Chemical & Pharmaceutical Co Ltd is engaged in the manufacturing and sales of Chinese and western medicine, cosmetics, beverage, normal instruments and medical instruments. Its segments include Medicine, Dietary supplement and Ingredients. The majority of the revenue is derived from the Medicine segment. Geographically it operates in Taiwan, Japan and Others with Taiwan generating the maximum revenue.
93GF Score
Get the complete analysis for TPE:1720
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1720 has been successfully added to your 
